Amprion
Healthcare Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10355 Science Center Dr Ste 240, San Die...Phone Number
(858) 461-6338Website
www.ampriondx.comRevenue
$7.3 MillionIndustry
About Amprion
Is Amprion your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Amprion launches new products
Earning: See what the market has to say on Amprion recently announced quarterly report
Check if Amprion has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Amprion
Click to see if Amprion had a recent Job posting/layoffs
Check out if Amprion is spiking on competitors!
Funding: Get notified immidiatlly once Amprion has new funding data
Amprion, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Amprion as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Amprion is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Amprion is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Amprion.
Amprion financials insights
Gather financial insights about Amprion, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series B
$15M
Amprion Tech Stack
A closer look at the technologies used by Amprion
Amprion News & Media
Amprion Announces Landmark Study in The Lancet Neurology
SAN DIEGO--(BUSINESS WIRE)--Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, announces a groundbreaking paper in The Lancet Neurology. The study demonstrates the ability of the synuclein seed amplification assay (synSAA) to differentiate between Type 1 and Type 2 synuclein seeds, addressing the critical need for accurate diagnosis of multiple system atrophy (MSA). This fatal synucleinopathy is often misdiagnosed as Parkinson’s diseaAmprion Honored to Win the 2024 BioTech Breakthrough Award ‘Clinical Diagnostics Solution of the Year’
SAN DIEGO--(BUSINESS WIRE)--Amprion, a global leader advancing diagnoses of neurodegenerative disorders, is closing out 2024 with several prestigious awards. Its novel assay, SAAmplify™-ɑSYN, won ‘Clinical Diagnostics Solution of the Year’ through the Biotech Breakthrough Awards Program. The Michael J. Fox Foundation (MJFF) also awarded Amprion’s co-founder, Dr. Claudio Soto, with ‘The Robert A. Pritzker Prize for Leadership in Parkinson's Research.’ Amprion’s SAAmplify-ɑSYN (formerly SYNTap®)
Top Healthcare Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Amprion
Amprion is the global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing. Amprions intellectual property surrounding SAA methodology extends to research, drug development, and commercialization. SAAmplify-SYN biomarker test (formerly SYNTap®) is the only seed amplification assay available to aid the diagnos... Read More